• In late July 2026, Corcept Therapeutics reported second-quarter net income of US$42.99 million, up from US$35.15 million a year earlier, with diluted earnings per share from continuing operations rising to US$0.36 from US$0.29.
• Alongside these stronger quarterly profits, the company raised its full-year 2026 revenue guidance to between US$1.1 billion and US$1.2 billion, signalling management’s confidence in its business momentum.
• We’ll now examine how Corcept’s upgraded 2026 revenue guidance reshapes the company’s investment narrative and longer-term growth assumptions.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Corcept Therapeutics Investment Narrative Recap

To own Corcept Therapeutics, you need to be comfortable with a story that still hinges on Korlym cash flows while the relacorilant franchise and oncology programs scale up. The stronger Q2 profit and higher 2026 revenue guidance are encouraging, but they do not remove the near term concentration risk around Korlym or the execution and regulatory uncertainty tied to relacorilant approvals.

The most relevant recent announcement here is Corcept’s decision to raise its 2026 revenue guidance to US$1.1 billion to US$1.2 billion. That upgrade sits against a backdrop of past pharmacy capacity constraints and ongoing payer pressure, making it an important data point for how quickly management expects to convert clinical and commercial progress, including relacorilant’s NDA resubmission, into realized top line growth.

Yet beneath the stronger guidance, investors should still be aware of Korlym’s heavy revenue concentration and the patent litigation overhang with Teva as...

Corcept Therapeutics' narrative projects $1.9 billion revenue and $910.1 million earnings by 2029. This requires 34.6% yearly revenue growth and about an $863 million earnings increase from $46.7 million today.

Uncover how Corcept Therapeutics' forecasts yield a $88.00 fair value, a 22% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in roughly US$1.9 billion of revenue and more than US$700 million of earnings by 2029, which is a far more ambitious path than the baseline view and could look either more achievable or stretched once the raised 2026 guidance and relacorilant’s regulatory risk are fully reflected in updated forecasts, so it is worth comparing these different narratives before deciding where you sit on that spectrum.

Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

No Opportunity In Corcept Therapeutics?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.